ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Dendrobium officinale polysaccharide ameliorate hyperlipidemia through LKB1/AMPK and CD36/PGC-1α/UCP1 activation and gut microbiota modulation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendrobium officinale polysaccharide (DOP) is recognized for its potential therapeutic effects on hyperlipidemia; however, its specific mechanisms in modulating lipid metabolism within hepatic and adipose tissues, along with its influence on the gut microbiota, have yet to be fully elucidated. Our study identified that the monosaccharide constituents of DOP comprise mannose, glucose, rhamnose, galactose, xylose, and arabinose. Network pharmacology analysis further indicated that the AMPK signaling pathway serves as a principal target of DOP. Using SD rats (8 weeks old, weighing 220-250 g), a hyperlipidemia model was established through a high-sugar, high-fat diet. Administration of DOP for 45 days resulted in significant reductions in total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), accompanied by an elevation in high-density lipoprotein cholesterol (HDL-C). Histopathological evaluation revealed an improvement in hepatic steatosis. At the molecular level within hepatic tissue, DOP treatment restored the expression of liver kinase B1 (LKB1) and the AMP-activated protein kinase (AMPK), while concurrently suppressing HMG-CoA reductase (HMGCR), sterol regulatory element-binding protein 1 (SREBF1), and phosphorylated acetyl-CoA carboxylase 1 (ACC1). In adipose tissue, DOP downregulated the cluster of differentiation 36 (CD36) expression and upregulated peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and uncoupling protein 1 (UCP1). Gut microbiota analysis demonstrated an increased abundance of Bacteroidota, Verrucomicrobiota, and Akkermansiaceae, alongside a decrease in Firmicutes and Actinobacteriota. Correlation analyses revealed that genera were correlated with serum lipid levels. Collectively, these findings suggest that DOP mitigates hyperlipidemia through modulation of the hepatic LKB1/AMPK signaling pathway and its downstream targets HMGCR, SREBF1, and ACC1, activation of the adipose CD36/PGC-1α/UCP1 pathway, and restoration of gut microbiota homeostasis, indicating a close relationship with the gut-liver axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.